AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11042989
Drug: 10 percent
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 percent CP whitening agent
Trial: 8778601
Drug: Regularly scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly scheduled inhaled albuterol
Trial: 8778601
Drug: As-needed inhaled
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As-needed inhaled albuterol
Trial: 2875904
Drug: Brompheniramine maleate
RxNorm normalized name: Brompheniramine Maleate
DrugBank: Brompheniramine (DB00835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brompheniramine maleate (12 mg twice daily in sustained release form)
Trial: 24115082
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab 162 mg every 2 weeks (q2w)
Trial: 24115082
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab 162 mg weekly (qw)
Trial: 24115082
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab 81 mg every 2 weeks (q2w)
Trial: 22152401
Drug: Pharmacotherapy +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy + clinical management (MED)
Trial: 22152401
Drug: Pill-placebo +
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill-placebo + clinical management (PBO)
Trial: 15301658
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus bupropion SR (150 mg per day)
Trial: 21507585
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus placebo
Trial: 9349066
Drug: morphine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (75 micrograms.kg‐1)
Trial: 3896355
Drug: Combination instruments
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination instruments (masker plus hearing aid)
Trial: 23891925
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg, twice daily)
Trial: 20374562
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/day) for 3 months
Trial: 20374562
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/day) for 9 months
Trial: 7981560
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/day)
Trial: 12168782
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg/day for 10 days
Trial: 12625969
Drug: Metronidazole treatment
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole treatment (rectally for at least 4 days)
Trial: 7496647
Drug: Paroxetine (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20, 40, or 60 mg)
Trial: 1784590
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg.3/day)
Trial: 6807568
Drug: Verapamil, 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 480 mg/day
Trial: 28296763
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg M-001
Trial: 28296763
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg M-001
Trial: 20935327
Drug: Cognitive-linguistic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-linguistic treatment (CLT), 6 months, at least 2 hours per week
Trial: 20935327
Drug: Communicative treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Communicative treatment, 6 months, at least 2 hours per week
Trial: 20935327
Drug: Cognitive-linguistic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-linguistic treatment (CLT)
Trial: 19522781
Drug: Home-based ecologically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based ecologically based family therapy (EBFT)
Trial: 19522781
Drug: Office-based functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based functional family therapy (FFT)
Trial: 15055821
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months treatment with growth hormone (2 IU/day)
Trial: 11218239
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (mean, 0.12 mg/kg/day) plus oral glutamine (mean, 28 g/day) and parenteral glutamine (mean, 5.2 g/day) for 28 days
Trial: 11218239
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone and glutamine treatment
Trial: 9355019
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (AT) for 18 +/- 6 months
Trial: 9355019
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (AT)
Trial: 3315478
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MPSS) 30 mg/kg
Trial: 31462735
Drug: Obinutuzumab (G)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance
Trial: 23030309
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (candesartan cilexetil 16 mg)
Trial: 23030309
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (candesartan cilexetil 16 mg)
Trial: 18044014
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of isoproterenol (20 mug/min) during repeat ablation
Trial: 15019120
Drug: Glutamine granules
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine granules 0.5 g/kg orally for 14 days
Trial: 15019120
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosage as glutamine) for 14 days
Trial: 9935254
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trovafloxacin once daily for 10 days
Trial: 7755476
Drug: cilazapril 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 2.5-5 mg per day
Trial: 7755476
Drug: atenolol 25-100
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 25-100 mg per day
Trial: 2971977
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose aerosol of 200 micrograms fenoterol plus 80 micrograms ipratropium bromide ('Duovent')
Trial: 2971977
Drug: Dry powder
RxNorm normalized name: Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder preparation for inhalation ('Inhalets') of 200 micrograms fenoterol plus 80 micrograms ipratropium bromide ('Duovent')
Trial: 28347865
Drug: Mechanical curettage
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical curettage with adjunct antimicrobial photodynamic therapy (aPDT)
Trial: 20848527
Drug: Boswelan (3×2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswelan (3×2 capsules/day; 400 mg each)
Trial: 19918682
Drug: Healer cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healer cream applied 3 times daily
Trial: 19918682
Drug: Nitroglycerine 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine 0.25% cream applied 3 times daily
Trial: 19918682
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% cream applied 3 times daily
Trial: 9580234
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + 750 mg UDA + fiber placebo
Trial: 9580234
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + 15 g Pp + UDA placebo
Trial: 3759281
Drug: L-carnitine, 2
RxNorm normalized name: L-Carnitine, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine, 2 g twice daily for 15 days
Trial: 24288121
Drug: Topotecan (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (0.75 mg/m²) on days 1, 2, and 3, etoposide (70 mg/m²) and cisplatin (20 mg/m²) on days 8, 9, and 10 (Arm A)
Trial: 24288121
Drug: Irinotecan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (50 mg/m²) and cisplatin (20 mg/m²) on days 1 and 8 followed by etoposide (85 mg/m² PO bid) on days 3 and 10 (Arm B)
Trial: 19095597
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg once daily for 4 weeks
Trial: 9797112
Drug: Liposomal lecithin
RxNorm normalized name: Lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal lecithin (1 mg/mL for 2 hours)
Trial: 2569381
Drug: Ceftriaxone 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 4 x 1 g i.m. every 2 days
Trial: 2569381
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G 1 million IU i.m. daily for 15 days
Trial: 28854534
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg i.v. after induction of anaesthesia
Trial: 26267418
Drug: Antidepressants (ADs)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants (ADs) plus mood stabilizers continued for up to 3 years after achieving euthymia for 2 months
Trial: 26267418
Drug: Antidepressants (ADs)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants (ADs) continued
Trial: 26267418
Drug: Antidepressants (ADs)
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants (ADs) discontinued
Trial: 23792189
Drug: Patient Education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Education plus Manual Therapy (PE + MT)
Trial: 22089463
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab 2‐4 mg/kg (± MTX) every 12 weeks
Trial: 22089463
Drug: golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 50 mg SC (± MTX) every 4 weeks
Trial: 22089463
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab (2‐4 mg/kg)
Trial: 10392323
Drug: Avitriptan (12.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan (12.7 mg)
Trial: 10392323
Drug: Avitriptan (25.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan (25.3 mg)
Trial: 10392323
Drug: Avitriptan (38.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan (38.0 mg)
Trial: 9133311
Drug: Diltiazem (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.3 mg/Kg bolus, followed by 0.0028 mg/Kg/min infusion if needed)
Trial: 9133311
Drug: Verapamil (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (75 micrograms/Kg bolus, with a second dose if needed)
Trial: 9133311
Drug: Sokolow protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sokolow protocol (i.v. digital plus oral quinidine 400 to 1,200 mg)
Trial: 3658286
Drug: Doxycycline 400
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 400 mg
Trial: 3346865
Drug: Metronidazole 1500
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 1500 mg
Trial: 19018865
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy including new drugs
Trial: 19018865
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of an alkylating drug with a novel agent
Trial: 12215058
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and sertraline
Trial: 12943944
Drug: Serotonergic antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic antidepressants
Trial: 28109543
Drug: Everolimus (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (1.5 mg or 3 mg) with reduced cyclosporine
Trial: 22795453
Drug: Extended-release mixed
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release mixed amphetamine salts (MAS-ER) and topiramate
Trial: 16218799
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Fenofibrate + Pravastatin)
Trial: 12359197
Drug: Daily aspiration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily aspiration of seroma
Trial: 10416042
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 100 mg twice daily
Trial: 7559695
Drug: Enoxaparin (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (administered at 12 hours preoperatively and 12 and 36 hours postoperatively)
Trial: 2795592
Drug: Tyramine infusion
RxNorm normalized name: tyramine
DrugBank: Tyramine (DB08841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine infusion (TI)
Trial: 25845222
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection of kakkonein (2 mL) into bilateral Fengchi (GB 20), once every other day for 8 weeks
Trial: 25845222
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of compound levodopa (125 mg, twice a day) for 8 weeks
Trial: 23975654
Drug: Vortioxetine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine co-administered with bupropion
Trial: 23975654
Drug: Vortioxetine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine co-administered with fluconazole
Trial: 23975654
Drug: Vortioxetine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine co-administered with ketoconazole
Trial: 23975654
Drug: Vortioxetine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine co-administered with rifampicin
Trial: 23975654
Drug: Vortioxetine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine co-administered with ethinyl estradiol/levonorgestrel
Trial: 23975654
Drug: Vortioxetine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine co-administered with 5'-hydroxyomeprazole
Trial: 17918294
Drug: Cisplatin 20
RxNorm normalized name: CISPLATIN 200MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 20 mg/m(2), days 1‐5, every 21 days (arm A, n=171)
Trial: 17918294
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m(2)/weekly (arm B, n=164)
Trial: 9294777
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of bovine TSH, 10 units daily for 3 days
Trial: 9294777
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of L‐triiodothyronine 75 micrograms for 7 days
Trial: 7870742
Drug: New generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generation antidepressants (maprotiline, mianserin, viloxazine, trazodone, nomifensine, fluvoxamine, fluoxetine)
Trial: 3346364
Drug: Sulpiride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (100 mg, three times daily for 4 days, then 50 mg, three times daily for 90 days)
Trial: 25023791
Drug: Intramyocardial bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial bone marrow cell (BMC) injection (97 ± 13 × 10(6) BMCs)
Trial: 22680341
Drug: Namisol® (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namisol® (5 mg THC) - Sublingual administration
Trial: 22680341
Drug: Namisol® (6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namisol® (6.5 mg and 8.0 mg THC) - Oral administration
Trial: 19763743
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DPO) targeting hemoglobin (Hb) of 12-13 g/dl
Trial: 19763743
Drug: Correction of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correction of anemia to 11 g/dl or more
Trial: 11952885
Drug: Simvastatin (S)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (S) 40 mg for 6 weeks, S 80 mg for 6 weeks, S 80 mg for 24 weeks
Trial: 11952885
Drug: Atorvastatin (A)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (A) 20 mg for 6 weeks, A 40 mg for 6 weeks, A 80 mg for 24 weeks
Trial: 11952885
Drug: Atorvastatin (A)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (A) 80 mg
Trial: 11952885
Drug: Simvastatin (S)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (S) 80 mg
Trial: 7617812
Drug: Lithium-TCA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium-TCA treatment
Trial: 7617812
Drug: TCA-placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCA-placebo treatment
Trial: 2095133
Drug: Ibuprofen sugar-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen sugar-coated tablets (Dolo-Dolgit) 600 mg
Trial: 2095133
Drug: Ibuprofen film-coated
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen film-coated tablets 600 mg (reference preparation)
Trial: 31697573
Drug: NNS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNS treatment (aspartame and sucralose)
Trial: 28157599
Drug: One Session
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Session Treatment for specific phobias
Trial: 24517053
Drug: Huzhang Tongfeng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huzhang Tongfeng Granule + Jinhuang Ointment (acute phase); Yinlian Tongfeng Granule (remission phase)
Trial: 24517053
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Sodium Sustained Release Capsule + Jinhuang Ointment (acute phase); Benzbromarone (remission phase)
Trial: 19505198
Drug: Zolpidem tartrate
RxNorm normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem tartrate extended-release taken in combination with escitalopram
Trial: 16918596
Drug: Topical hyaluronic
RxNorm normalized name: hyaluronate Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hyaluronic acid (HA) 0.2%
Trial: 3296734
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide (2 mg/kg/dose)
Trial: 3296734
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (2 mg/kg/dose)
Trial: 3296734
Drug: Prochlorperazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (10 mg/dose)
Trial: 3296734
Drug: Metoclopramide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (oral and intravenous)
Trial: 3296734
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral and intravenous metoclopramide
Trial: 27935580
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance treatment
Trial: 27935580
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance treatment in patients aged >74 years